These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 25618509)

  • 1. What is the place of new SGLT-2 inhibitors in therapy and on the formulary?
    Mehr SR; Zimmerman MP
    Am J Manag Care; 2014 Mar; 20(4 Spec No.):E1. PubMed ID: 25618509
    [No Abstract]   [Full Text] [Related]  

  • 2. [The role of SGLT-2 inhibitors in the treatment of type 2 diabetes].
    Rupprecht H
    MMW Fortschr Med; 2015 Jan; 157(1):55-8. PubMed ID: 25743304
    [No Abstract]   [Full Text] [Related]  

  • 3. Sodium glucose transporter 2 inhibition: a new approach to diabetes treatment.
    Bloomgarden Z
    J Diabetes; 2013 Sep; 5(3):225-7. PubMed ID: 23714218
    [No Abstract]   [Full Text] [Related]  

  • 4. [Introduction].
    García SD
    Med Clin (Barc); 2013 Sep; 141 Suppl 2():1-2. PubMed ID: 24444516
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of sodium-glucose cotransporter type 2 inhibitors in older adults with type 2 diabetes mellitus.
    Mikhail N
    South Med J; 2015 Feb; 108(2):91-6. PubMed ID: 25688893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-glucose cotransporter 2 inhibitors for treating diabetes mellitus.
    Goldberg N; Fralick M
    CMAJ; 2017 May; 189(20):E724. PubMed ID: 28536128
    [No Abstract]   [Full Text] [Related]  

  • 7. [Glycosuria with SGLT-2 inhibitors--a new treatment approach for type 2 diabetes mellitus].
    Rosak C; Forst T
    MMW Fortschr Med; 2012 Dec; 154 Suppl 4():95-101. PubMed ID: 23326927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabetic kidney disease in 2017: A new era in therapeutics for diabetic kidney disease.
    Wanner C
    Nat Rev Nephrol; 2018 Feb; 14(2):78-80. PubMed ID: 29307892
    [No Abstract]   [Full Text] [Related]  

  • 9. [SGLT-2 inhibition with canagliflozin: a new option for the treatment of type 2 diabetes].
    Seufert J
    Dtsch Med Wochenschr; 2014 Feb; 139 Suppl 2():S52-8. PubMed ID: 24481633
    [No Abstract]   [Full Text] [Related]  

  • 10. [Positive experience with SGLT-2 inhibitor in general practice].
    Fath R
    MMW Fortschr Med; 2015 Jul; 157(13):83. PubMed ID: 26206058
    [No Abstract]   [Full Text] [Related]  

  • 11. The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus.
    Riser Taylor S; Harris KB
    Pharmacotherapy; 2013 Sep; 33(9):984-99. PubMed ID: 23744749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hot Topics in Primary Care: Role of the Kidney and SGLT-2 Inhibition in Type 2 Diabetes Mellitus.
    Miller K; Miller EM
    J Fam Pract; 2015 Dec; 64(12 Suppl):S54-8. PubMed ID: 26845015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium glucose co-transporter 2 (SGLT2) inhibition with canagliflozin in type 2 diabetes mellitus.
    Said S; Hernandez GT
    Cardiovasc Hematol Agents Med Chem; 2013 Sep; 11(3):203-6. PubMed ID: 24025022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
    Davidson JA; Kuritzky L
    Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ketonuria/ketonemia associated with the use of sodium-glucose cotransporter 2 (SGLT-2) inhibitors in type 2 diabetes: A report of three cases from New Delhi, India.
    Ghosh A; Gupta R; Misra A
    J Diabetes; 2016 Sep; 8(5):738-9. PubMed ID: 27085074
    [No Abstract]   [Full Text] [Related]  

  • 16. [Canagliflozin monotherapy: clinical study data in type 2 diabetes mellitus].
    Matthaei S
    Dtsch Med Wochenschr; 2014 Feb; 139 Suppl 2():S59-64. PubMed ID: 24481634
    [No Abstract]   [Full Text] [Related]  

  • 17. Canagliflozin: a new hope in the antidiabetic armamentarium.
    Katsi VK; Michalakeas CA; Grassos CE; Vamvakou GD; Lekakis JP; Tousoulis D; Stefanadis CI; Makris TK; Kallikazaros IE
    Recent Pat Cardiovasc Drug Discov; 2013 Dec; 8(3):216-20. PubMed ID: 24359233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Glucose renal excretion as diabetes treatment: From an old diagnostic method to a new way of treatment].
    Dalama B; Biagetti B; Mesa J
    Med Clin (Barc); 2016 May; 146(10):460-4. PubMed ID: 26823105
    [No Abstract]   [Full Text] [Related]  

  • 19. Sodium glucose transporter 2 (sglt2) inhibitors: Current status in clinical practice.
    Dutta D; Kalra S
    J Pak Med Assoc; 2014 Oct; 64(10):1203-6. PubMed ID: 25823168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.